Company Overview of TARIS BioMedical, Inc.
TARIS BioMedical, Inc. operates a pharmaceutical company that develops therapies using drug delivery technologies to treat bladder diseases. It develops a pipeline of therapeutics to leverage common and minimally invasive urologic procedures to deliver and maintain therapeutic drug levels in target tissues. The company offers LiRIS that is used to deliver lidocaine directly into the bladder to relieve symptoms associated with interstitial cystitis, such as bladder pain and voiding dysfunction. TARIS BioMedical, Inc. was formerly known as Certus Biomedical Inc. and changed its name to TARIS Biomedical Inc. in May 2009. TARIS Biomedical Inc. was founded in 2008 and is based in Lexington, Massa...
99 Hayden Avenue
Lexington, MA 02421
Founded in 2008
Key Executives for TARIS BioMedical, Inc.
Chief Business Officer and Senior Vice President
Compensation as of Fiscal Year 2014.
TARIS BioMedical, Inc. Key Developments
TARIS BioMedical Enters Research Collaboration with AstraZeneca for Improved Bladder Cancer Treatments
Oct 16 13
TARIS Biomedical announced that it has entered into a research collaboration with AstraZeneca to evaluate novel treatments for bladder cancer. Under the terms of the agreement, the companies will work together to evaluate multiple novel cancer therapeutics by employing the TARIS(R) proprietary bladder delivery platform in combination with targeted cancer therapeutics from AstraZeneca. The TARIS(R) delivery platform is a soft, flexible system deployed into and retrieved from the bladder using standard urological office procedures. It is designed to provide continuous local delivery to the bladder for days to weeks, depending on the therapeutic application. Furthermore, AstraZeneca has an exclusive option to take a license to the products resulting from the collaboration. This could combine the ability to target both the right tissue - the tumour, with the right genetically targeted therapy and therefore represent a step change in the treatment of this disease.
TARIS BioMedical, Inc. Secures $12.5 Million in Additional Financing; Initiates Phase 2 Trial of Lead Product Candidate
Apr 2 13
TARIS BioMedical, Inc. announced that it has raised an additional $12.5 million financing round through its existing investors, Flagship Ventures, Flybridge Capital Partners, Polaris Partners and Third Rock Ventures. Including this round, TARIS(R) has raised a total of $49.8 million.
The company also announced dosing of its first patient in its second randomized, placebo controlled Phase 2 study of LiRIS(R) in Interstitial Cystitis. This study is being conducted in the US and Canada, and is currently open for enrollment. In addition to Interstitial Cystitis, TARIS(R) is developing a pipeline of novel, targeted therapies designed to treat a variety of bladder diseases, such as bladder cancer and urinary incontinence, utilizing its novel targeted bladder delivery system.
TARIS BioMedical, Inc. Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013
Feb 7 13
TARIS BioMedical, Inc. Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013 . Venue: Centre Covencions International Barcelona, Plaça de Willy Brandt, 11-14, 08019 Barcelona, Spain.
Similar Private Companies By Industry
Recent Private Companies Transactions